Impact of Angptl3 siRNA treatment on NS markers
Angptl3 siRNA treatment attenuated hypertriglyceridemia and improved pathologic kidney markers in puromycin-treated NS animals. Data are presented as means ± S.D.
| CTL (n = 9) | NS (n = 8) | NS + siRNA (n = 9) | |
|---|---|---|---|
| Systolic blood pressure baseline (mm Hg) | 97.4 ± 7.6 | 96.3 ± 12.1 | 89.3 ± 14.8 |
| Systolic blood pressure final (mm Hg) | 97.1 ± 6.6 | 115.8 ± 11.7* | 97.4 ± 10.4† |
| Body weight baseline (g) | 276.4 ± 9.7 | 277.8 ± 4.3 | 278.9 ± 6.9 |
| Body weight final (g) | 475.7 ± 35.7 | 393.3 ± 29.5* | 384.3 ± 37.9* |
| Hb (g/dl) | 13.7 ± 0.9 | 12.8 ± 1.6 | 13.5 ± 0.8 |
| HCT (%) | 40.2 ± 2.3 | 39.3 ± 1.4 | 39.8 ± 2.0 |
| Kidney (g) | 3.1 ± 0.3 | 5.0 ± 0.6* | 5.1 ± 0.4* |
| Liver (g) | 12.2 ± 1.7 | 12.2 ± 1.3 | 12.5 ± 2.9 |
| Serum BUN (ml/dl) | 15.8 ± 2.6 | 19.1 ± 3.0* | 16.1 ± 3.4 |
| Serum creatinine (mg/min) | 0.26 ± 0.03 | 0.32 ± 0.1* | 0.30 ± 0.1 |
| Creatinine clearance (ml/min) | 2.6 ± 0.58 | 1.7 ± 0.4* | 2.2 ± 0.5† |
| Albumin (g/dl) | 3.6 ± 0.6 | 2.5 ± 0.5* | 2.9 ± 0.5* |
| Serum TC (mg/dl) | 93.0 ± 27.0 | 411.2 ± 147.2* | 372.3 ± 103.3* |
| Serum TG (mg/dl) | 52.2 ± 13.0 | 307.5 ± 88.9* | 89.7 ± 78.4† |
| Serum LDL | 42.6 ± 6.3 | 205.3 ± 89.6* | 192.4 ± 72.1* |
↵* P < 0.05 vs. control; †P < 0.05 Angptl3 siRNA treatment group-NS + siRNA vs. NS. HCT - Hematocrit, BUN-Blood Urea Nitrogen, TC-Total cholesterol, CTL-Control, NS- Nephrotic syndrome.